среда, 14 марта 2012 г.

Schering-Plough swings to 4Q profit

Drugmaker Schering-Plough Corp. posted a fourth-quarter profit that topped estimates as lingering buyout charges for Organon Biosciences NV decreased, but revenue suffered from a stronger U.S. dollar and lagging cholesterol drug sales.

The company continues to record quarterly charges for its November 2007 buyout of Organon, but they are substantially less compared to a year earlier. Meanwhile, the benefit from Organon product sales continues driving revenue.

Schering-Plough earned $480 million, or 27 cents per share, compared with a loss of $3.36 billion, or $2.08 per share, a year earlier because of hefty buyout charges. Schering says revenue rose 17 …

Комментариев нет:

Отправить комментарий